search
Back to results

Left Bundle Branch Area Pacing in Patients After TAVR (PLANET)

Primary Purpose

Aortic Valve Stenosis, AV Block, Pacing-Induced Cardiomyopathy

Status
Active
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Left bundle branch area pacing
Right ventricular pacing
Sponsored by
Ludwig-Maximilians - University of Munich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Valve Stenosis focused on measuring left bundle branch area pacing, av block, right ventricular pacing, aortic valve stenosis, TAVR, ECG

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Successful TAVR implantation for classical (high flow high gradient), symptomatic aortic valve stenosis
  • LVEF ≥50%
  • Guideline-based indication for pacing due to AV block III°, AV block II°, or symptomatic bradycardic atrial fibrillation with an expecteed ventricular pacing burden >20%
  • Signed informeed conseent to study participation

Exclusion Criteria:

  • LVEF <50%
  • Expected pacing burden <20%
  • Pre-existing implanted cardiac device
  • Participation in a concurring interventional trial
  • age <18 years
  • Current preegnancy
  • life expectancy <6 months

Sites / Locations

  • LMU Klinikum

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention Arm

Control Arm

Arm Description

Patients are randomized to receive left bundle branch are pacing due to higher degree AV block

Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.

Outcomes

Primary Outcome Measures

QRS duration
QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads

Secondary Outcome Measures

QRS duration
QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads
QRS duration
QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads
Death of any cause
Death of any cause
Death of any cause
Death of cardio-vascular cause
Death of cardio-vascular cause
Death of cardio-vascular cause
Re-hospitalization due to heart failure
Re-hospitalization due to heart failure
Re-hospitalization due to heart failure
Change in left ventricular ejection fraction
Change in left ventricular ejection fraction
Change in left ventricular ejection fraction
Change in echocardiographic left ventricular enddiastolic diameter
Change in echocardiographic left ventricular enddiastolic diameter
Change in echocardiographic left ventricular enddiastolic diameter
Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency
Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency
Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency
Echocardiographic assessment of right ventricular ejection fraction
Echocardiographic assessment of right ventricular ejection fraction
Echocardiographic assessment of right ventricular ejection fraction
Change in New York heart failure classification status
Change in New York heart failure classification status
Change in New York heart failure classification status
Change in laboratory biomarkers NT-proBNP
Change in laboratory biomarkers NT-proBNP
Change in laboratory biomarkers NT-proBNP
Change in functional status by 6 minute walk
Change in functional status by 6 minute walk
Change in functional status by 6 minute walk
Change in EQ-5D quality of life
Change in EQ-5D quality of life
Change in EQ-5D quality of life
Occurence of arrhythmias
Occurence of arrhythmias
Occurence of arrhythmias

Full Information

First Posted
August 9, 2021
Last Updated
January 30, 2023
Sponsor
Ludwig-Maximilians - University of Munich
search

1. Study Identification

Unique Protocol Identification Number
NCT05024279
Brief Title
Left Bundle Branch Area Pacing in Patients After TAVR
Acronym
PLANET
Official Title
Pacing of the Left Bundle Branch Area NEcessitated After TAVR
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 6, 2021 (Actual)
Primary Completion Date
April 2023 (Anticipated)
Study Completion Date
April 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ludwig-Maximilians - University of Munich

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Prospective, randomized, single center clinical trial to compare the outcome of left bundle branch area pacing versus right ventricular apical pacing in patients with higher degree atrio-ventricular block and a normal left ventricular function after transcatheter aortic valve replacement.
Detailed Description
Transcatheter aortic valve replacement (TAVR) is a well-established treatment of aortic valve stenosis. Yet, requiry of permanent pacing due to new onset atrio-ventricular conduction block remains a frequent complication. Standard right ventricular pacing (RVP) at high pacing burden may lead to deterioration of left ventricular function. Left-Bundle-Area Pacing (LBBP) is a new, innovative method of physiological ventricular stimulation resulting in narrow, physiological QRS complexes. In this prospective, randomized, single center clinica trial, patients are included after TAVR and with normal left ventricular function who require pacing due to a higher degree atriao-ventricular block with an anticipated high pacing burden. Patients will be randomized to receive either left bundle branch area pacing (intervention) or right ventricular apical pacing (control). The results will confirm the feasibility of LBBP in patients following TAVR. Results will further investigate the primary outcome of a clinically relevant QRS narrowing and a combination of exploratory secondary endpoints including clinical outcomes, functional status, laboratory biomarkers, and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis, AV Block, Pacing-Induced Cardiomyopathy
Keywords
left bundle branch area pacing, av block, right ventricular pacing, aortic valve stenosis, TAVR, ECG

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1:1 randomization
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention Arm
Arm Type
Experimental
Arm Description
Patients are randomized to receive left bundle branch are pacing due to higher degree AV block
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
Patients are randomized to receive standard right ventricular pacing due to higher degree AV block.
Intervention Type
Device
Intervention Name(s)
Left bundle branch area pacing
Intervention Description
Left bundle branch area pacing will be applied as established in the literature using commercially available equipment. In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed.
Intervention Type
Device
Intervention Name(s)
Right ventricular pacing
Intervention Description
Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
Primary Outcome Measure Information:
Title
QRS duration
Description
QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads
Time Frame
3 months
Secondary Outcome Measure Information:
Title
QRS duration
Description
QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads
Time Frame
12 months
Title
QRS duration
Description
QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads
Time Frame
24 months
Title
Death of any cause
Time Frame
3 months
Title
Death of any cause
Time Frame
12 months
Title
Death of any cause
Time Frame
24 months
Title
Death of cardio-vascular cause
Time Frame
3 months
Title
Death of cardio-vascular cause
Time Frame
12 months
Title
Death of cardio-vascular cause
Time Frame
24 months
Title
Re-hospitalization due to heart failure
Time Frame
3 months
Title
Re-hospitalization due to heart failure
Time Frame
12 months
Title
Re-hospitalization due to heart failure
Time Frame
24 months
Title
Change in left ventricular ejection fraction
Time Frame
3 months
Title
Change in left ventricular ejection fraction
Time Frame
12 months
Title
Change in left ventricular ejection fraction
Time Frame
24 months
Title
Change in echocardiographic left ventricular enddiastolic diameter
Time Frame
3 months
Title
Change in echocardiographic left ventricular enddiastolic diameter
Time Frame
12 months
Title
Change in echocardiographic left ventricular enddiastolic diameter
Time Frame
24 months
Title
Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency
Time Frame
3 months
Title
Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency
Time Frame
12 months
Title
Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency
Time Frame
24 months
Title
Echocardiographic assessment of right ventricular ejection fraction
Time Frame
3 months
Title
Echocardiographic assessment of right ventricular ejection fraction
Time Frame
12 months
Title
Echocardiographic assessment of right ventricular ejection fraction
Time Frame
24 months
Title
Change in New York heart failure classification status
Time Frame
3 months
Title
Change in New York heart failure classification status
Time Frame
12 months
Title
Change in New York heart failure classification status
Time Frame
24 months
Title
Change in laboratory biomarkers NT-proBNP
Time Frame
3 months
Title
Change in laboratory biomarkers NT-proBNP
Time Frame
12 months
Title
Change in laboratory biomarkers NT-proBNP
Time Frame
24 months
Title
Change in functional status by 6 minute walk
Time Frame
3 months
Title
Change in functional status by 6 minute walk
Time Frame
12 months
Title
Change in functional status by 6 minute walk
Time Frame
24 months
Title
Change in EQ-5D quality of life
Time Frame
3 months
Title
Change in EQ-5D quality of life
Time Frame
12 months
Title
Change in EQ-5D quality of life
Time Frame
24 months
Title
Occurence of arrhythmias
Time Frame
3 months
Title
Occurence of arrhythmias
Time Frame
12 months
Title
Occurence of arrhythmias
Time Frame
24 months
Other Pre-specified Outcome Measures:
Title
Pacemaker-associated complications
Time Frame
3 months
Title
Pacemaker-associated complications
Time Frame
12 months
Title
Pacemaker-associated complications
Time Frame
24 months
Title
procedural implantation success
Description
dichotomous yes / no
Time Frame
basline
Title
Implantation procedure duration
Time Frame
baseline
Title
Fluoroscopy duration
Time Frame
baseline
Title
Fluoroscopy dose
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Successful TAVR implantation for classical (high flow high gradient), symptomatic aortic valve stenosis LVEF ≥50% Guideline-based indication for pacing due to AV block III°, AV block II°, or symptomatic bradycardic atrial fibrillation with an expecteed ventricular pacing burden >20% Signed informeed conseent to study participation Exclusion Criteria: LVEF <50% Expected pacing burden <20% Pre-existing implanted cardiac device Participation in a concurring interventional trial age <18 years Current preegnancy life expectancy <6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moritz F Sinner, MD, MPH
Organizational Affiliation
LMU Klinikum, Dept. of Cardiology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stephanie Fichtner, MD
Organizational Affiliation
LMU Klinikum, Dept. of Cardiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
LMU Klinikum
City
Munich
State/Province
BY
ZIP/Postal Code
81377
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Left Bundle Branch Area Pacing in Patients After TAVR

We'll reach out to this number within 24 hrs